New hope for pancreatic cancer: targeted combo trial for BRCA/PALB2 patients
NCT ID NCT06783140
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 21 times
Summary
This study tests a new combination of chemotherapy drugs (NABPLAGEM) against the standard combo for people with advanced pancreatic cancer that has a BRCA1/2 or PALB2 gene mutation. The goal is to see if the new combo works better at shrinking tumors and helping people live longer. About 10 participants will join this early-stage trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PALB2 GENE MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.